SYDNEY, Jan. 30, 2014 /PRNewswire/ -- Novogen Limited (ASX: NRT; NASDAQ: NVGN), an oncology drug development company, today announced it will host a corporate update with Graham Kelly, Ph.D., Novogen Group Executive Chairman and Chief Executive Officer, and David Brown, Ph.D., Chief Scientific Officer on Friday, February 7, 2014 at 8:00 a.m. (Sydney local time). This corresponds to Thursday, February 6, 2014 at 4:00 p.m. U.S. Eastern Standard Time.
(Logo: http://photos.prnewswire.com/prnh/20131220/NY36990LOGO)
A live audio webcast with slides will be available on the company's website, www.novogen.com as part of the webcast.To participate in the live teleconference, please dial the following numbers fifteen minutes before the call is scheduled to begin: U.S. and Canada, 877-303-5846; Australia, 1800005989 (toll-free) or 02-8223-9773 (toll). Callers in other countries should dial 315-625-3081 (toll charges apply). The archived webcast will be available for two weeks on the company's website, or until February 21, 2014.
About Novogen Limited
Novogen is an public, Australian biotechnology company whose shares trade on both the Australian Securities Exchange ('NRT') and NASDAQ ('NVGN'). The Company is based in Sydney, Australia, and with a U.S. office in New Haven, Connecticut. The Company has two main drug technology platforms known as super-benzopyrans (SBP) and anti-tropomyosins (ATM). SBP drugs target cancer stem cells and are being developed for the treatment of ovarian cancer and glioblastoma. ATM drugs target the cancer cell cytoskeleton and are being developed for the treatment of melanoma, prostate cancer and neuroblastoma. Novogen has entered into a joint venture with Yale University known as CanTx Inc. with the aim of developing personalized chemotherapy for patients with ovarian cancer.
Further information is available on the Company's website, www.novogen.com.
For Further Information Contact:
David Carey/Tanner Kaufman
Lazar Partners Ltd.
212 867 1762
dcarey@lazarpartners.com
tkaufman@lazarpartners.com
SOURCE Novogen Limited
